GET DAILY SIGNALSPrecigen (PGEN) Shares Decline -38% Over 30 Days as Competition Emerges in RRP Market
Key Takeaways
- PGEN shares fell roughly 38% over the trailing 30 days, with the decline accelerating in early November.
- The sharpest single-session move came after the FDA approved a competing recurrent respiratory papillomatosis (RRP) therapy from Inovio, sending PGEN down about 25%.
- The selloff overshadowed otherwise strong fundamentals: third-quarter PAPZIMEOS net revenue rose 37% sequentially to $72.9 million.
- Precigen reported net income of $35.8 million and positive operating cash flow of $11.9 million in Q3, ahead of its own guidance.
- Analyst sentiment remained constructive, with Citizens raising its price target to $12 from $11 while maintaining an Outperform rating.
- For additional context on valuation, results, and outlook, explore Price Targets, Earnings, and Forecast pages.
- Discover how automated strategies are tracking this and other tickers on Trending AI Robots.
Precigen (PGEN) Company Overview and Market Position
Precigen, Inc. is a Germantown, Maryland-based biopharmaceutical company that develops gene and cell therapies across immuno-oncology, autoimmune disorders, and infectious diseases. The company's proprietary platforms include AdenoVerse immunotherapy and UltraCAR-T, alongside its UltraPorator electroporation device and the Exemplar research-models business.
The company's commercial flagship is PAPZIMEOS (zopapogene imadenovec, formerly PRGN-2012), which received full FDA approval in August 2025 as the first therapy for adults with recurrent respiratory papillomatosis (RRP), a rare condition caused by HPV types 6 and 11. The pivotal program demonstrated a 51% complete response rate, with patients remaining surgery-free for up to five years. Investors follow PGEN closely because PAPZIMEOS represents a first-in-class, first-to-market commercial franchise with an estimated addressable U.S. population of about 27,000 adults. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Precigen (PGEN) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, PGEN declined approximately 38%, falling from a closing price near $7.36 to roughly $4.53. The move was not gradual; much of the damage occurred in a concentrated span in early November, when shares slid from around $6.94 to an intraday low near $3.92 before stabilizing.
The quarterly picture tells a similar but more dramatic story. After rallying through September to a 52-week high near $8.98 intraday, PGEN reversed course and has since given back a substantial portion of those gains. The stock's trajectory shifted from a steady uptrend driven by strong commercial execution into a sharp correction triggered by a competitive threat, illustrating how quickly sentiment can turn in a single-product biopharmaceutical story.
What Drove PGEN Stock Price in the Last 30 Days
The dominant catalyst was competitive. On November 2, 2026, the FDA granted approval to Inovio Pharmaceuticals' Voceryq for recurrent respiratory papillomatosis, the same indication targeted by Precigen's PAPZIMEOS. The news triggered an approximate 25% single-day decline in PGEN as investors recalibrated expectations for market share erosion and potential pricing pressure.
The selloff occurred despite a strong earnings report. On November 4, Precigen reported third-quarter results showing PAPZIMEOS net revenue of $72.9 million, up 37% quarter-over-quarter, total revenue of $74.1 million, net income of $35.8 million, and positive operating cash flow of $11.9 million — a quarter ahead of its prior guidance. Analysts responded constructively, with Citizens raising its price target to $12 from $11 and Raymond James reiterating a $12 target, but the competitive overhang outweighed the positive financials in the near term. From what I see, this highlights how external news can override solid execution in the short term.
What Drove PGEN Stock Performance Over the Last Quarter
The broader quarterly trend reflects a collision between strong execution and rising competitive risk. Through September and October, PGEN climbed on the back of accelerating PAPZIMEOS adoption — more than 500 patients had initiated treatment within just over a year of launch, supported by payer coverage spanning over 315 million U.S. lives and a permanent J-code effective April 1, 2026.
That momentum, combined with the FDA's platform designation for the AdenoVerse technology and ongoing EMA review of a marketing authorization application, underpinned investor enthusiasm through late September. The subsequent reversal, however, was driven primarily by the approval of a competing RRP therapy, which introduced uncertainty about Precigen's long-term competitive positioning despite its first-mover advantage, broad label, and durable efficacy data.
PGEN Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor several factors going forward. The most immediate is competitive execution: how the Inovio Voceryq launch unfolds and whether Precigen can defend its first-mover position given PAPZIMEOS's 51% complete response rate and durable efficacy profile. Continued quarterly revenue growth, gross margin stability, and cash flow generation will be closely scrutinized.
Additional catalysts include the EMA's review of the marketing authorization application for zopapogene imadenovec, potential ex-U.S. partnership decisions, and clinical updates from the PRGN-2009 HPV immunotherapy program. The company's forthcoming R&D Day, expected to feature new Phase 2 data and an expanded AdenoVerse strategy, may also influence sentiment. Macroeconomic conditions and broader biotech sector sentiment remain relevant risk factors, as do execution risks tied to reimbursement and patient adoption rates. I’m watching this closely as the competitive landscape evolves.
Exploring Tickeron AI Tools for Deeper Analysis
In my research on names like PGEN, I often turn to Tickeron’s AI Trading Bots to see how automated strategies are responding to similar market moves. These tools help filter through volatility by applying data-driven approaches across different timeframes, giving a clearer view of potential patterns without replacing personal judgment. It has become a useful part of my process for tracking biotech names where news can shift sentiment quickly.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PGEN's RSI Indicator climbs out of oversold territory
The RSI Oscillator for PGEN moved out of oversold territory on November 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 32 similar instances when the indicator left oversold territory. In 31 of the 32 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +12.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where PGEN advanced for three days, in 206 of 240 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
PGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PGEN as a result. In 81 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
PGEN moved below its 50-day moving average on October 15, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for PGEN crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 77%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for PGEN entered a downward trend on November 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 29 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. PGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (36.727) is normal, around the industry mean (3.498). P/E Ratio (-4.178) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (32.258) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 99 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biotechnology company, which engages in the research and development of synthetic biology technologies.
Industry Biotechnology
Advertisement